Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Axsome Therapeutics Inc AXSM

Healthcare Biotechnology
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor... see more

Recent & Breaking News (NDAQ:AXSM)

Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation

GlobeNewswire December 10, 2018

Axsome Therapeutics Expands Loan Agreement with Silicon Valley Bank Providing Additional Growth Capital Related to AXS-12 Product Candidate

GlobeNewswire November 27, 2018

Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings

GlobeNewswire November 21, 2018

Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference

GlobeNewswire November 19, 2018

Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder

GlobeNewswire November 14, 2018

The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Benzinga.com  November 9, 2018

Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update

GlobeNewswire November 9, 2018

Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018

GlobeNewswire November 1, 2018

Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation

GlobeNewswire October 18, 2018

46 Biggest Movers From Yesterday

Benzinga.com  October 18, 2018

A Peek Into The Markets: US Stock Futures Down Ahead Of Fed Minutes

Benzinga.com  October 17, 2018

Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy

GlobeNewswire October 17, 2018

Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy

GlobeNewswire October 16, 2018

Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy

GlobeNewswire October 16, 2018

Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire October 12, 2018

Axsome Therapeutics to Focus on Growing Core CNS Portfolio; Establishes Axsome Pain and Primary Care Business Unit to Enhance Value of Non-CNS Assets

GlobeNewswire October 11, 2018

Axsome Therapeutics Announces $8.9 Million Registered Direct Offering

GlobeNewswire September 28, 2018

Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 24, 2018

Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation

GlobeNewswire September 19, 2018

Axsome Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

GlobeNewswire August 28, 2018